JelikaLite was awarded the National Science Foundation SBIR Phase II grant
JelikaLite was awarded the National Science Foundation SBIR Phase II grant
Sign up for Early Access
banner

JelikaLite is a clinical stage medical technology company developing a transformational neuromodulation platform for unmet needs in developmental pediatric disorders. Our lead product is focused on Autism Spectrum Disorder (ASD).

ASD is a lifelong developmental disorder. The rates continue to rise, the cause remains unknown, and current solutions are inadequate. Autistic individuals frequently have difficulties with communication, social interactions, repetitive behavior and focus, impacting their ability to integrate into society. We believe that all children can lead fulfilling and productive lives.
That is why we are developing Cognilum, an innovative solution to enhance the child's communication skills while reducing a child's troublesome autism symptoms, enabling them to improve their lives. Cognilum is a therapeutic wearable device, providing non-invasive brain stimulation with near-infrared light, sensors and a machine learning personalization platform.

How It Works

Therapeutic wearable device, with LEDs and sensors.
Personalized AI platform.
Continuous Feedback Loop
Learn More

Problem

There are currently no FDA-approved treatments for the core symptoms of ASD

  • 30% remain non-verbal
  • Lifetime cost : $1 – $3.5MM
  • 85% remain unemployed
  • Autism rates keep growing worldwide
  • Over 70% of parents of autistic children suffer from depression
Learn More

Why Cognilum?

  • 1
    At JelikaLite, we recognize the pressing need for effective FDA-approved treatments targeting the core symptoms of ASD. With unwavering dedication and cutting-edge innovation, our lead product - Cognilum - is poised to pave the way for significant change in the field of ASD management.
  • 2
    Cognilum is designed to improve responsiveness, speech, and social interaction.
    * These statements are based on the results of JelikaLite’s Phase 1 feasibility trials and have not yet been evaluated by the FDA
  • 3
    It is the first home-based LED-based device for children with autism. It is designed to be easily administered in the child's home, with time flexibility, privacy, and no need for the physical presence of a therapist.
  • 4
    Watch results of the 2021 double-blind clinical study using Cognilum
    Watch results of the 2022 open label clinical study using Cognilum
  • 5
    Received FDA Breakthrough Device Designation and FDA Non-Significant Risk Device Study Designation
Learn More